These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 33769675)

  • 1. Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy.
    Lingvay I; Greenberg M; Gallo S; Shi H; Liu J; Gantz I
    Diabetes Obes Metab; 2021 Jul; 23(7):1640-1651. PubMed ID: 33769675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
    Dagogo-Jack S; Liu J; Eldor R; Amorin G; Johnson J; Hille D; Liao Y; Huyck S; Golm G; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Obes Metab; 2018 Mar; 20(3):530-540. PubMed ID: 28921862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
    Rosenstock J; Frias J; Páll D; Charbonnel B; Pascu R; Saur D; Darekar A; Huyck S; Shi H; Lauring B; Terra SG
    Diabetes Obes Metab; 2018 Mar; 20(3):520-529. PubMed ID: 28857451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
    Aronson R; Frias J; Goldman A; Darekar A; Lauring B; Terra SG
    Diabetes Obes Metab; 2018 Jun; 20(6):1453-1460. PubMed ID: 29419917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
    Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.
    Ji L; Liu Y; Miao H; Xie Y; Yang M; Wang W; Mu Y; Yan P; Pan S; Lauring B; Liu S; Huyck S; Qiu Y; Terra SG
    Diabetes Obes Metab; 2019 Jun; 21(6):1474-1482. PubMed ID: 30830724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
    Amin NB; Wang X; Jain SM; Lee DS; Nucci G; Rusnak JM
    Diabetes Obes Metab; 2015 Jun; 17(6):591-598. PubMed ID: 25754396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV.
    Budoff MJ; Davis TME; Palmer AG; Frederich R; Lawrence DE; Liu J; Gantz I; Derosa G
    Diabetes Ther; 2021 May; 12(5):1279-1297. PubMed ID: 33721213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
    Gallo S; Charbonnel B; Goldman A; Shi H; Huyck S; Darekar A; Lauring B; Terra SG
    Diabetes Obes Metab; 2019 Apr; 21(4):1027-1036. PubMed ID: 30614616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
    Terra SG; Focht K; Davies M; Frias J; Derosa G; Darekar A; Golm G; Johnson J; Saur D; Lauring B; Dagogo-Jack S
    Diabetes Obes Metab; 2017 May; 19(5):721-728. PubMed ID: 28116776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
    Cannon CP; McGuire DK; Pratley R; Dagogo-Jack S; Mancuso J; Huyck S; Charbonnel B; Shih WJ; Gallo S; Masiukiewicz U; Golm G; Cosentino F; Lauring B; Terra SG;
    Am Heart J; 2018 Dec; 206():11-23. PubMed ID: 30290289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.
    Dagogo-Jack S; Pratley RE; Cherney DZI; McGuire DK; Cosentino F; Shih WJ; Liu J; Frederich R; Mancuso JP; Raji A; Gantz I
    BMJ Open Diabetes Res Care; 2021 Oct; 9(1):. PubMed ID: 34620621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
    Dagogo-Jack S; Frederich R; Liu J; Cannon CP; Shi H; Cherney DZI; Cosentino F; Masiukiewicz U; Gantz I; Pratley RE
    J Clin Endocrinol Metab; 2023 Jul; 108(8):2042-2051. PubMed ID: 36702781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies.
    Pratley R; Dagogo-Jack S; Charbonnel B; Patel S; Hickman A; Liu J; Tarasenko L; Pong A; Ellison MC; Huyck S; Gantz I; Terra SG
    Diabetes Obes Metab; 2020 Dec; 22(12):2276-2286. PubMed ID: 32700421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Hollander P; Hill J; Johnson J; Wei Jiang Z; Golm G; Huyck S; Terra SG; Mancuso JP; Engel SS; Lauring B; Liu J
    Curr Med Res Opin; 2019 Aug; 35(8):1335-1343. PubMed ID: 30760125
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
    Liu J; Patel S; Cater NB; Wu L; Huyck S; Terra SG; Hickman A; Darekar A; Pong A; Gantz I
    Diabetes Obes Metab; 2020 Apr; 22(4):574-582. PubMed ID: 31797522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.
    Dagogo-Jack S; Cannon CP; Cherney DZI; Cosentino F; Liu J; Pong A; Gantz I; Frederich R; Mancuso JP; Pratley RE
    Diabetes Obes Metab; 2022 Jul; 24(7):1245-1254. PubMed ID: 35266296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
    Cherney DZI; Cosentino F; Pratley RE; Dagogo-Jack S; Frederich R; Maldonado M; Liu J; Pong A; Liu CC; Cannon CP;
    Diabetes Obes Metab; 2022 Jun; 24(6):1114-1122. PubMed ID: 35233908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus.
    Liu J; Tarasenko L; Pong A; Huyck S; Patel S; Hickman A; Mancuso JP; Ellison MC; Gantz I; Terra SG
    Curr Med Res Opin; 2020 Jul; 36(7):1097-1106. PubMed ID: 32324065
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus.
    Liu J; Tarasenko L; Pong A; Huyck S; Wu L; Patel S; Hickman A; Mancuso JP; Gantz I; Terra SG
    Curr Med Res Opin; 2020 Aug; 36(8):1277-1284. PubMed ID: 32324082
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.